跳至主要内容
临床试验/NCT03064269
NCT03064269招募中1 期

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2017年3月1日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
10
试验地点
1
主要终点
The complete remission (CR) rate

研究概览

简要总结

This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.

详细描述

CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

盲法说明

Open Label

入排标准

年龄范围
10 Years 至 60 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with CD19 positive central nervous system B-cell acute lymphocytic leukemia
  • ALT/ AST 《 3x normal
  • Creatinine 《 3x normal
  • Signed informed consent

排除标准

  • Active hepatitis B , hepatitis C or HIV infection
  • Uncontrolled active infection
  • Pregnancy or breast-feeding women
  • Survival less than four weeks

结局指标

主要结局

The complete remission (CR) rate

时间窗: Participants will be followed for the duration of the treatment, an expected average of 12 months

The safety of the humanized CD19 CAR-T cells treatment will be evalated and the maximum tolerated dose will be determined

次要结局

未报告次要终点

研究者

发起方
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验